Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Nuvectis Pharma, Inc. (NVCT) had Income from Continuous Operations of $-19.00M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-19.00M |
|
-- |
|
-- |
|
$19.85M |
|
$-19.85M |
|
$0.85M |
|
$-19.00M |
|
$-19.00M |
|
$-19.00M |
|
|
Income from Continuous Operations |
$-19.00M |
$-19.00M |
|
$-19.00M |
|
$-19.85M |
|
$-19.85M |
|
17.11M |
|
17.11M |
|
$-1.11 |
|
$-1.11 |
|
| Balance Sheet Financials | |
$18.61M |
|
-- |
|
-- |
|
$18.61M |
|
$8.89M |
|
-- |
|
-- |
|
$8.89M |
|
$9.71M |
|
$9.71M |
|
$9.71M |
|
19.50M |
|
| Cash Flow Statement Financials | |
$-12.25M |
|
-- |
|
$11.65M |
|
$19.13M |
|
$18.53M |
|
$-0.59M |
|
$4.86M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.09 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.25M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-195.61% |
|
-195.61% |
|
-102.11% |
|
-195.61% |
|
$0.50 |
|
$-0.72 |
|
$-0.72 |
|